<DOC>
	<DOC>NCT01728298</DOC>
	<brief_summary>The primary objective of the trial is to evaluate the dose-response relationship with regards to change in immunological parameters and safety for SLITone ULTRA house dust mite mix in adult subjects with moderate to severe HDM allergic rhinitis.</brief_summary>
	<brief_title>A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Aged 18 or older Moderate to severe persistent HDM allergic rhinitis with or without asthma Moderate to severe HDM allergic rhinitis symptoms during a baseline period Positive skin prick test response (wheal diameter ≥ 3 mm) Positive specific IgE ≥ IgE Class 2, ≥ 0.70 kU/l) Previous treatment with immunotherapy with House dust mite immunotherapy Ongoing treatment with any allergen specific immunotherapy product Reduced lung function Clinical history of uncontrolled asthma Inflammatory conditions in the oral cavity with severe symptoms History of anaphylaxis with cardiorespiratory symptoms History of recurrent generalised urticaria A history of drug induced facial angioedema or hereditary angiooedema Any clinically relevant chronic disease (≥3 months duration) Systemic disease affecting the immune system Immunosuppressive treatment Currently treated with tricyclic antidepressants; catecholamineMethyltransferase inhibitors and mono amine oxidase inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>House Dust Mite</keyword>
	<keyword>allergy</keyword>
	<keyword>rhinitis</keyword>
	<keyword>asthma</keyword>
</DOC>